The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
The FDA also recommends that prescribed users reduce their caloric intake and increase their exercise The weight loss drug ...
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
FDA has approved the first prescription drug, Zepbound, for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...
If you have sleep apnea and obesity, tirzepatide Zepbound may offer relief and support weight loss. Ask your doctor if it’s a ...
The U.S. Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating ...
The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...
Key Takeaways Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with ...
The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback